%D8%B3%D9%8A%D8%B3%D8%A8%D9%84%D8%A7%D8%AA%D9%8A%D9%86%D8%B3%DB%8C%D8%B3%E2%80%8C%D9%BE%D9%84%D8%A7%D8%AA%DB%8C%D9%86Cisplat%C3%ADCategory:CisplatinCisplatinCisplatinCisplatinCisplatino%D8%B3%DB%8C%D8%B3%E2%80%8C%D9%BE%D9%84%D8%A7%D8%AA%DB%8C%D9%86SisplatiiniCisplatine%D7%A6%D7%99%D7%A1%D7%A4%D7%9C%D7%90%D7%98%D7%99%D7%9F%E0%A4%B8%E0%A4%BF%E0%A4%B8%E0%A4%AA%E0%A5%8D%E0%A4%B2%E0%A5%87%E0%A4%9F%E0%A4%BF%E0%A4%A8%D5%91%D5%AB%D5%BD%D5%BA%D5%AC%D5%A1%D5%BF%D5%AB%D5%B6SisplatinCisplatino%E3%82%B7%E3%82%B9%E3%83%97%E3%83%A9%E3%83%81%E3%83%B3%EC%8B%9C%EC%8A%A4%ED%94%8C%EB%9D%BC%ED%8B%B4%D0%A6%D0%B8%D1%81%D0%BF%D0%BB%D0%B0%D1%82%D0%B8%D0%BDCisplatine%E0%AC%B8%E0%AC%BF%E0%AC%B8%E0%AC%AA%E0%AD%8D%E0%AC%B2%E0%AC%BE%E0%AC%9F%E0%AC%BF%E0%AC%A8CisplatynaCisplatinaCisplatin%C4%83%D0%A6%D0%B8%D1%81%D0%BF%D0%BB%D0%B0%D1%82%D0%B8%D0%BDCisplatinCisplatinCisplatin%E0%B8%8B%E0%B8%B4%E0%B8%AA%E0%B8%9E%E0%B8%A5%E0%B8%B2%E0%B8%95%E0%B8%B4%E0%B8%99Sisplatin%D0%A6%D0%B8%D1%81%D0%BF%D0%BB%D0%B0%D1%82%D0%B8%D0%BDCisplatinQ412415%E9%A1%BA%E9%93%82
about
sameAs
subependymal giant cell astrocytomabreast cancerhepatoblastomaovarian cancerhead and neck cancerprostate cancerhead and neck squamous cell carcinomagerm cell cancerlung benign neoplasmgastric adenocarcinomalung oat cell carcinomachildhood cerebral astrocytomaHodgkin's lymphoma, mixed cellularitylymphosarcomastomach cancerspindle cell sarcomatransitional cell carcinomatongue squamous cell carcinomatesticular cancernon-small-cell lung carcinomaesophageal cancermultiple myelomaamelanotic melanomabladder cancerosteosarcomaneuroblastoma, susceptibility tobone sarcomalaryngeal cancerneuroblastoma
P2176
P3781
Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract CancerDe-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell CarcinomaBGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaStudy of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical CancerARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsStandard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell TumorsClinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell LymphomaGEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract CancerOral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract CancerAutologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple MyelomaA Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node MetastasisRadiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction DesignStudy of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of CholangiocarcinomaUARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionMaximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCCCisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.SIMPLE Chemotherapy for NK Lymphoma/LeukaemiaPD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal CarcinomaEtoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung CancerTrastuzumab in HER2-positive Biliary Tract CancerTrial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint AtezolizumabAdjuvant Treatment of Apatinib in Nasopharyngeal CarcinomaGP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPCTrial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal CancersThe Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing ChemotherapyPostoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell CarcinomaStudy of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial CancerIrinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck CancerMethotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder CancerTrial of E10A in Head and Neck CancerRandomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung CancerEvaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCCPhase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLCPaclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By SurgeryRadiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial CancerSorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III MelanomaCisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma
P4844
cellular response to cisplatinresponse to cisplatinVeliparib / Cisplatin combination therapyfluorouracil / cisplatin combination therapyalisertib / cisplatin combination therapycisplatin / pemetrexed combination therapyVinorelbine / cisplatin combination therapycisplatin / paclitaxel combination therapyprexasertib / cisplatin / olaparib combination therapycisplatin / gemcitabine combination therapyetoposide / mitomycin / cisplatin combination therapydoxorubicin / etoposide / cisplatin combination therapy
P527
An Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effectPeroxide is a key mediator of Bcl-2 down-regulation and apoptosis induction by cisplatin in human lung cancer cellsInducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cellsNitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitinationHydroxyl radical mediates cisplatin-induced apoptosis in human hair follicle dermal papilla cells and keratinocytes through Bcl-2-dependent mechanismEffects of exposure to chemicals on noise-induced hearing lossSurface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studiesMechanism of vascular endothelial growth factor expression mediated by cisplatin in human ovarian cancer cellsHybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse predictionEvaluation of exposures to healthcare personnel from cisplatin during a mock demonstration of intra-operative intraperitoneal chemotherapy administrationHealth hazard evaluation report: HETA-2009-0121-3106, evaluation of exposures to healthcare personnel from cisplatin during a mock interperitoneal operation, University Medical Center, Las Vegas, NevadaEvaluation of exposures to healthcare personnel from cisplatin during a mock interperitoneal operationHealth hazard evaluation report: evaluation of chemotherapy drug exposure in an outpatient infusion centerVEGF expression is inhibited by cisplatin at the transcriptional level through HIF-1 alpha expressionHydrogen peroxide mediates the apoptotic effect of cisplatin by downregulating bcl-2 through ubiquitin-proteasomal degradationCarbon nanotubes induce apoptosis resistance through FLICE-inhibitory proteinRecent advances in the understanding of noise interactionsAntibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotidesIs there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent.Mechanisms of cisplatin ototoxicity: theoretical review.Overcoming cisplatin resistance in chemotherapy by biomineralization.Use of cultured cells of kidney origin to assess specific cytotoxic effects of nephrotoxins.Electrochemotherapy increases local control after incomplete excision of a recurring penile fibrosarcoma in a stallion.On the Mechanism of Action of the Antitumor Drug cis-Platin (cis-DDP) and its Second Generation Derivatives.Cisplatin resistance associated with PARP hyperactivation.Impairment of the renal p-aminohippurate transport induced by 6-hydroxydopamine.Enhancing alkylating agent resistance through ERCC2 gene transfection in human glioma cell line.Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy.Establishment of Effective Mouse Model of Premature Ovarian Failure Considering Treatment Duration of Anticancer Drugs and Natural Recovery TimeCisplatin-induced cardiotoxicity with midrange ejection fraction: A case report and review of the literatureModulation of RAB7A Protein Expression Determines Resistance to Cisplatin through Late Endocytic Pathway Impairment and Extracellular Vesicular SecretionTriplet chemotherapy with docetaxel, cisplatin and S-1 for unresectable advanced squamous cell carcinoma of the esophagus: phase I/II trial resultsMicroRNA-217 acts as a tumor suppressor and correlates with the chemoresistance of cervical carcinoma to cisplatinPlatinum Resistance in Ovarian Cancer: Role of DNA RepairUpregulated microRNA-193a-3p is responsible for cisplatin resistance in CD44(+) gastric cancer cellsConcurrent chemotherapy in oropharyngeal cancer: Cisplatin winsMetformin attenuates hypoxia-induced resistance to cisplatin in the HepG2 cell lineIn Vivo Anticancer Activity of a Nontoxic Inert Phenolato Titanium Complex: High Efficacy on Solid Tumors Alone and Combined with Platinum DrugsCisplatinProtein binding, sister chromatid exchange and expression of oncogene proteins in patients treated with cisplatinum (cisDDP)-based chemotherapy
P921
description
Arzneistoff, Zytostatikum
@de
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
complexe de platine
@fr
name
Cisplatin
@de
Cisplatin
@sh
Cisplatin
@sl
Cisplatin
@sr
Cisplatin
@vi
Cisplatino
@es
Cisplatino
@it
Cisplatină
@ro
Sisplatiini
@fi
Sisplatin
@id
type
label
Cisplatin
@de
Cisplatin
@sh
Cisplatin
@sl
Cisplatin
@sr
Cisplatin
@vi
Cisplatino
@es
Cisplatino
@it
Cisplatină
@ro
Sisplatiini
@fi
Sisplatin
@id
altLabel
(SP-4-2)-Diammindichloridoplatin(II)
@de
15663-27-1
@fr
CDDP
@cy
CDDP
@en
CDDP
@ja
CIS-DDP
@cy
CIS-DDP
@en
Cis platin
@nl
Cis platina
@nl
Cis-DDP
@cy
prefLabel
Cisplatin
@de
Cisplatin
@sh
Cisplatin
@sl
Cisplatin
@sr
Cisplatin
@vi
Cisplatino
@es
Cisplatino
@it
Cisplatină
@ro
Sisplatiini
@fi
Sisplatin
@id